Orthopedic Use of BPC 157 Sports Med Review FDA Peptide Reclassification 2026: What It Means for Providers FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with Deep Dive: Regulatory Status of Popular Compounded Peptides Holt Law